[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"American Contract Systems Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":93},{"warningLetters":4,"total":92},[5,32,50,70],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1172,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-11-12T14:20:00Z\">11\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-11-01T04:00:00Z\">11\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowens-minor-inc-dba-american-contract-systems-inc-695683-11012024\">Owens &amp; Minor, Inc. dba American Contract Systems, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward A. Pesicka\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Owens &amp; Minor, Inc. dba American Contract Systems, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9130 Lockwood Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mechanicsville\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>23116\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:edpesicka@owens-minor.com\"> edpesicka@owens-minor.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 695683\u003Cbr>\n\u003Cbr>\nDear Mr. Pesicka:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, American Contract Systems, (ACS) Inc., in Tiffin OH, FEI 3008492337, on August 5 through 14, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile convenience kits, such as the C-Section Pack (pack number WECS27G). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Daniel R. Wright, VP, Global QARA, Owens &amp; Minor, Inc., dated September 5, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance of incoming product to ensure that incoming product is inspected, tested, or otherwise verified as conforming to specified requirements, and that acceptance or rejection is documented, as required by 21 CFR 820.80(b). For example:\u003C\u002Fp>\n\n\u003Cp>On at least four occasions, from January 2024 through July 2024, your firm accepted sterilization bag lots (86149183, 86471442, 86740750, 86149178) that failed your thickness requirements. Your Receiving Procedure, RV-01, includes minimum and maximum acceptance criteria for these bags to ensure they are free from defects that may adversely affect gas injection, sealing, or diffusion characteristics during your ethylene oxide (EO) sterilization processes. Acceptance activities for these 4 lots were being performed by ACS personnel at sister facilities in Florida. Each of these lots were deemed acceptable and the lots were used for EO processing at this Tiffin, OH facility, as well as other ACS facilities.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You indicated that CAPA 2024-0021 was opened but did not provide a copy that describes the preventive actions you are planning to address this serious observation.\u003C\u002Fp>\n\n\u003Cp>Your response states that on August 6, 2024, you placed a hold on all raw material sterilization bags at all ACS locations, including Tiffin, OH. All finished goods in ACS manufacturing locations and O&amp;M distribution centers were then placed on distribution hold on August 7, 2024, while you investigated these failures. Your investigation included performing a retest of all available bags in inventory at your Fort Myers facility and you indicated that all retests passed your specifications. However, your response did not provide a systemic response describing how your firm will prevent this significant failure from recurring.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\u003C\u002Fp>\n\n\u003Cp>You did not implement your Design Control Procedure, DE-01.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has not completed design verification and validation activities for 25 different FDA product codes in use at this facility, to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process, as required by 21 CFR 820.30(g).\u003C\u002Fp>\n\n\u003Cp>For example, two out of 26 components that are included in your C-Section Pack (pack number WECS27G) have not been verified as acceptable for your EO sterilization process. The “CAUTERY| ES ROCKER COATED SMOKE EVAC NS” is classified as a “medium” risk component and there was no documentation that this component was evaluated, as required by your “design verification and validation activities” that are described in your design control procedure.\u003C\u002Fp>\n\n\u003Cp>Your Design Control Procedure, DE-01, requires component evaluation be performed as part of your design verification and validation process, including your C-Section Pack, designated as FDA Code OHM, class 2. The procedure also requires that all these review records be included in the design history file.\u003C\u002Fp>\n\n\u003Cp>Also, your firm did not have complete design history files for 25 different FDA product codes being manufactured at your facility, as required by 21 CFR 820.30(j).\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that it is not adequate. You acknowledged documentation indicating component approval for products was lacking at this facility and were not part of your DHF’s. You now plan to remediate all components and approve all DHFs, by January 31, 2025, in part to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process. Your firm did not provide enough detail to describe how you plan on prioritizing and implementing this review for all 25 product codes in use at this location.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>. As part of your response to this observation, please describe how you will complete this review of components to ensure that only devices with complete DHF’s, including complete component evaluations, are currently being distributed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 695683 when replying. If you have any questions about the contents of this letter, please contact: Gina Brackett, EAT Assistant Director at (513) 288-7055 or gina.brackett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>\nDirector\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>, Operations Manager, \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>@owens-minor.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEdward A. Pesicka\n\nRecipient Title\n\nPresident & Chief Executive Officer\n\nOwens & Minor, Inc. dba American Contract Systems, Inc.\n\n9130 Lockwood Boulevard\n\nMechanicsville, VA 23116\n\nUnited States\n\nedpesicka@owens-minor.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 695683\n\nDear Mr. Pesicka:\n\nDuring an inspection of your firm, American Contract Systems, (ACS) Inc., in Tiffin OH, FEI 3008492337, on August 5 through 14, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures sterile convenience kits, such as the C-Section Pack (pack number WECS27G). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Daniel R. Wright, VP, Global QARA, Owens & Minor, Inc., dated September 5, 2024, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance of incoming product to ensure that incoming product is inspected, tested, or otherwise verified as conforming to specified requirements, and that acceptance or rejection is documented, as required by 21 CFR 820.80(b). For example:\n\nOn at least four occasions, from January 2024 through July 2024, your firm accepted sterilization bag lots (86149183, 86471442, 86740750, 86149178) that failed your thickness requirements. Your Receiving Procedure, RV-01, includes minimum and maximum acceptance criteria for these bags to ensure they are free from defects that may adversely affect gas injection, sealing, or diffusion characteristics during your ethylene oxide (EO) sterilization processes. Acceptance activities for these 4 lots were being performed by ACS personnel at sister facilities in Florida. Each of these lots were deemed acceptable and the lots were used for EO processing at this Tiffin, OH facility, as well as other ACS facilities.\n\nWe reviewed your firm’s response and concluded that it is not adequate. You indicated that CAPA 2024-0021 was opened but did not provide a copy that describes the preventive actions you are planning to address this serious observation.\n\nYour response states that on August 6, 2024, you placed a hold on all raw material sterilization bags at all ACS locations, including Tiffin, OH. All finished goods in ACS manufacturing locations and O&M distribution centers were then placed on distribution hold on August 7, 2024, while you investigated these failures. Your investigation included performing a retest of all available bags in inventory at your Fort Myers facility and you indicated that all retests passed your specifications. However, your response did not provide a systemic response describing how your firm will prevent this significant failure from recurring.\n\n(b)(4)\n\n2. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).\n\nYou did not implement your Design Control Procedure, DE-01.\n\nSpecifically, your firm has not completed design verification and validation activities for 25 different FDA product codes in use at this facility, to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process, as required by 21 CFR 820.30(g).\n\nFor example, two out of 26 components that are included in your C-Section Pack (pack number WECS27G) have not been verified as acceptable for your EO sterilization process. The “CAUTERY| ES ROCKER COATED SMOKE EVAC NS” is classified as a “medium” risk component and there was no documentation that this component was evaluated, as required by your “design verification and validation activities” that are described in your design control procedure.\n\nYour Design Control Procedure, DE-01, requires component evaluation be performed as part of your design verification and validation process, including your C-Section Pack, designated as FDA Code OHM, class 2. The procedure also requires that all these review records be included in the design history file.\n\nAlso, your firm did not have complete design history files for 25 different FDA product codes being manufactured at your facility, as required by 21 CFR 820.30(j).\n\nWe reviewed your firm’s response and concluded that it is not adequate. You acknowledged documentation indicating component approval for products was lacking at this facility and were not part of your DHF’s. You now plan to remediate all components and approve all DHFs, by January 31, 2025, in part to ensure that all components being placed in your convenience kits have been reviewed and verified to undergo your sterilization process. Your firm did not provide enough detail to describe how you plan on prioritizing and implementing this review for all 25 product codes in use at this location.\n\n(b)(4). As part of your response to this observation, please describe how you will complete this review of components to ensure that only devices with complete DHF’s, including complete component evaluations, are currently being distributed.\n\n(b)(4)\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 695683 when replying. If you have any questions about the contents of this letter, please contact: Gina Brackett, EAT Assistant Director at (513) 288-7055 or gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nRDML Sean M. Boyd, MPH, USPHS\n\nDirector\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc: (b)(4) , Operations Manager, (b)(4) @owens-minor.com","Owens & Minor, Inc. dba American Contract Systems, Inc.","owens-minor-inc-dba-american-contract-systems-inc-695683-11012024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fowens-minor-inc-dba-american-contract-systems-inc-695683-11012024","2026-10-26T08:09:39.746067+00:00","Warning Letter","Issued","2024-11-12","695683","Medical Devices","Edward A. Pesicka","2026-08-19T18:45:50.726+00:00","VIA Electronic Mail","2024-11-01",{"id":33,"raw":34,"subject":14,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":20,"letter_url":43,"updated_at":44,"action_type":23,"case_status":24,"posted_date":45,"marcs_cms_no":46,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":49,"medical_device_id":20,"response_letter_date":20},520,[35,36,37,11,14,13,13,13],"\u003Ctime datetime=\"2025-10-28T04:00:00Z\">10\u002F28\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025\">Contec Medical Systems Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kun “James” Hu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Contec Medical Systems Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 112 Qinhuang West Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Economic and Technical Development Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Qinhuangdao Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>066004\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>Dear Kun “James” Hu:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\u003Cp>A. The cause of nonconformities identified are not adequately investigated.\u003C\u002Fp>\u003Cp>B. Corrective actions taken are not documented per your firm’s CAPA procedure.\u003C\u002Fp>\u003Cp>C. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\u003C\u002Fp>\u003Cp>D. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\u003C\u002Fp>\u003Cp>B. Test reports do not confirm that design outputs meet design inputs. For example,\u003C\u002Fp>\u003Cp>i. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\u003C\u002Fp>\u003Cp>ii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\u003C\u002Fp>\u003Cp>C. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\u003C\u002Fp>\u003Cp>D. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\u003C\u002Fp>\u003Cp>The adequacy of the response dated July 1, 2025, cannot be determined at this time.\u003C\u002Fp>\u003Cp>While your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\u003C\u002Fp>\u003Cp>The response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\u003C\u002Fp>\u003Cp>The adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\u003C\u002Fp>\u003Cp>Given the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\u003C\u002Fp>\u003Cp>Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003Cbr>Bram Zuckerman&nbsp;&nbsp;\u003Cbr>Director Office of Cardiovascular Devices\u003Cbr>Office of Product Evaluation and Quality&nbsp;&nbsp;\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC:\u003Cbr>Marco Mu\u003Cbr>MID-LINK INTERNATIONAL CO., Ltd\u003Cbr>2219 Rimlang Drive, Suite 301\u003Cbr>Bellingham, Washington, US 98226\u003Cbr>Phone: 702-209-5185\u003Cbr>Fax: 360-925-3199\u003Cbr>Email: us.agent@mid-link.net\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nKun “James” Hu\n\nRecipient Title\n\nCEO\n\nContec Medical Systems Co., Ltd.\n\nNo. 112 Qinhuang West Street\n\nEconomic and Technical Development Zone\n\nQinhuangdao Shi\n\nHebei Sheng, 066004\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nOctober 2, 2025\nDear Kun “James” Hu:\nDuring an inspection of your firm located in Qinhuangdao, Hebei, China on June 9, 2025 through June 12, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CMS 8000 Patient Monitor, CMS600P2PLUS B-Ultrasound Diagnostic System, CMS1700B Color Doppler Ultrasound Diagnostic System, CMS 9000 Patient Monitor, PO30 Pulse Oximeter, Pocket Fetal Doppler. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Kun “James” Hu, CEO dated July 1, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). For example,\nA. The cause of nonconformities identified are not adequately investigated.\nB. Corrective actions taken are not documented per your firm’s CAPA procedure.\nC. The preventive action of creating the procedure, “Cybersecurity Management Plan, Version 1, Effective 6\u002F5\u002F2025” was not documented as completed prior to closing CAPA number 20250227M on 3\u002F18\u002F2025.\nD. Verification activities performed to verify corrective and preventive actions were effective are not adequately documented. Specifically, you have not verified that customers are correctly interpreting actions to be taken in response to your open recall (Z-1764-2025).\nThe response dated July 1, 2025, is not adequate. In \"FEI 3006979678,OBS1,WS2025061201-English\" you provided the revised procedures, training records, and reopened the cited CAPAs for further corrective actions. However, you have not performed a retroactive review of your CAPAs to ensure you have adequately investigated the cause of nonconformities, documented corrective actions taken per your updated CAPA procedure, and documented the verification activities performed to verify corrective and preventive actions were effective. Further, your responses do not address the verification of corrective and preventive action effectiveness for your open recall (Z-1764-2025). As such, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate CAPA procedures in accordance with 21 CFR 820.100(a).\n2. Failure to adequately establish and maintain procedures for validating the device design, as required by 21 CFR 820.30(g). For example:\nA. Test plans created to validate device software designs do not ensure validation testing is performed under adequately defined operating conditions. For example, test plans do not include established acceptance criteria prior to testing.\nB. Test reports do not confirm that design outputs meet design inputs. For example,\ni. Two security risks were found in the B-Ultrasound Diagnostic testing and your firm failed to document the patch created to shut down the function of the ports as a deviation from the test plan.\nii. The Security Test Report for the Color Doppler Ultrasound Diagnostic System did not include Network Segmentation, Zone Boundary Protection, and General Purpose, person-to-person communication restriction testing as identified as required in the Test Plan.\nC. Software design validations are not documented in device DHFs. For example, your firm did not have the software Test Plans for the B-Ultrasound Diagnostic System cleared under K232895 or the software Test Plan for the Color Doppler Ultrasound Diagnostic System cleared under K232908 in the respective DHF.\nD. Your firm failed to adequately implement your risk management procedure for the CMS 8000 software.\nThe adequacy of the response dated July 1, 2025, cannot be determined at this time.\nWhile your response provided updated procedures and test plans, it appears your response did not include complete test reports. Therefore, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate design validation in accordance with 21 CFR 820.30(g).\n3. Failure to adequately establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, complaints received via eCommerce sites and complaints received via international country officials are not reviewed and evaluated for reportability. Specifically, several complaints from eCommerce sites and one from Canada’s Medical Devices and Clinical Compliance Directorate were not logged in the complaint log for handling via your firm’s complaint handling procedure and were not evaluated for reportability to the FDA. Additionally, feedback associated with user error or known product quality degradation associated with component longevity (cables, power cord, USB cable, etc.) are not documented as complaints for trending or investigation.\nThe response dated July 1, 2025, is not adequate. Your response included updated procedures and training records; however, you have not performed a retroactive review of complaints received through eCommerce sites or international country officials to ensure you have adequately received, reviewed, and evaluated these complaints. Further, you have not provided evidence to support the adequate systemic implementation of your revised procedures and adequate complaint receiving, reviewing, and evaluating in accordance with 21 CFR 820.198(a).\n4. Failure to adequately maintain records at a location that is reasonably accessible to responsible officials of the manufacturer and to employees of the FDA, as required by 21 CFR 820.180. For example: the inspector asked to be taken to the location where the software test plan for the B-Ultrasound Diagnostic System could be found and your firm's Deputy Vice Manager for Certification and Registration indicated that test plans are not maintained at your firm for validation testing performed by third party vendors.\nThe adequacy of your response dated July 1, 2025, cannot be determined at this time. Your response revised the Product Certification and Registration Work Instruction and provided the training records on the revised instruction. However, you have not provided evidence to support the adequate systemic implementation of your revised work instruction and adequate records maintenance in accordance with 21 CFR 820.180.\nCorrections and Removals Violation\nOur inspection also revealed that your firm’s CMS8000 Patient Monitor devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to include a copy of all communications regarding the correction or removal in the report, as required by 21 CFR 806.10(c)(12). For example, you included a paragraph in the customer notification letter sent to consignees for an open recall (Z-1764-2025) that was omitted from the version of the letter sent to the FDA as part of the written report.\nGiven the serious nature of the violations of the Act, all devices manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violation(s) described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Jennifer Kozen at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 675091 when replying. If you have any questions about the contents of this letter, please contact: Jennifer Kozen at 301-796-5813 or Jennifer.Kozen@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems.\nYour firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nBram Zuckerman\nDirector Office of Cardiovascular Devices\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC:\nMarco Mu\nMID-LINK INTERNATIONAL CO., Ltd\n2219 Rimlang Drive, Suite 301\nBellingham, Washington, US 98226\nPhone: 702-209-5185\nFax: 360-925-3199\nEmail: us.agent@mid-link.net","Contec Medical Systems Co., Ltd.","contec-medical-systems-co-ltd-717941-10022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcontec-medical-systems-co-ltd-717941-10022025","2026-10-26T08:08:17.623451+00:00","2025-10-28","717941","Kun “James” Hu","2026-08-19T16:12:22.676+00:00","2025-10-02",{"id":51,"raw":52,"subject":56,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":20,"letter_url":63,"updated_at":64,"action_type":23,"case_status":65,"posted_date":66,"marcs_cms_no":67,"product_type":27,"closeout_date":68,"issuing_office":11,"recipient_name":20,"body_fetched_at":69,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":66,"medical_device_id":20,"response_letter_date":20},3493,[53,54,55,11,56,13,57,13],"\u003Ctime datetime=\"2021-03-04T05:17:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-03042021\">Cantronic Systems Inc.\u003C\u002Fa>","Device Adulterated and Misbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-07202023\">\u003Ctime datetime=\"2023-07-25T04:00:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cantronic Systems Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>#8-62 Fawcett Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coquitlam\u003C\u002Fspan> \u003Cspan>BC\u003C\u002Fspan> \u003Cspan>V3K 6V5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jzahn@cantronics.com %E2%80%93 James Zahn\"> jzahn@cantronics.com – James Zahn\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.cantronics.com on February 11, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the FeverScan M3000N, FeverScan M3000L, LGC300 Body Temperature Scanner, FeverScan M3000B, FeverScan M3000SD, FeverScan M3000S, FeverScan M3000P02, FeverScan M3000P03, FeverScan M3000P04, and FeverScan M3000P05 (collectively,“Temperature Scanners”), for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), your Temperature Scanners are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\u003C\u002Fp>\n\n\u003Cp>Your Temperature Scanners are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.cantronics.com\u002F, includes statements that indicate that your Temperature Scanners are intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“The FeverScan M3000N is ideal for mass temperature screening in public transport situations.” [Published on your website, https:\u002F\u002Fwww.cantronics.com\u002Findex.php\u002Ftemperature-screening-cameras]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cul>\n\t\u003Cli>“The FeverScan M3000P04 is capable of evaluating multiple people in real time” [Published on the FeverScan M3000P04 datasheet, https:\u002F\u002Fwww.cantronics.com\u002Fimages\u002Fdatasheet\u002FFeverScan-M3000P04-.pdf]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n&nbsp;\u003Cbr>\nYour firm’s response should be sent to:\u003Cbr>\n&nbsp;\u003Cbr>\nAttn: CAPT Alan Stevens\u003Cbr>\nActing Director, Division of Drug Delivery and General Hospital Devices,\u003Cbr>\nand Human Factors\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nDocument Control Center (DCC) – WO66-G609\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n&nbsp;\u003Cbr>\nRefer to the reference number CMS 613542 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at \u003Ca href=\"mailto:Jake.Lindstrom@fda.hhs.gov\">Jake.Lindstrom@fda.hhs.gov\u003C\u002Fa> or \u003Cspan>(301) 796-5716\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC:&nbsp;Dallas Thomas\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FDAbasics LLC\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15815 SW 11th Court Rd\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ocala, FL 34473\u003Cbr>\n&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; \u003Ca href=\"mailto:dallas@fdabasics.com\">dallas@fdabasics.com\u003C\u002Fa>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nCantronic Systems Inc.\n\n#8-62 Fawcett Rd\n\nCoquitlam BC V3K 6V5\n\nCanada\n\njzahn@cantronics.com – James Zahn\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.cantronics.com on February 11, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the FeverScan M3000N, FeverScan M3000L, LGC300 Body Temperature Scanner, FeverScan M3000B, FeverScan M3000SD, FeverScan M3000S, FeverScan M3000P02, FeverScan M3000P03, FeverScan M3000P04, and FeverScan M3000P05 (collectively,“Temperature Scanners”), for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), your Temperature Scanners are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\n\nYour Temperature Scanners are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fwww.cantronics.com\u002F, includes statements that indicate that your Temperature Scanners are intended to scan multiple individuals simultaneously, including:\n\n“The FeverScan M3000N is ideal for mass temperature screening in public transport situations.” [Published on your website, https:\u002F\u002Fwww.cantronics.com\u002Findex.php\u002Ftemperature-screening-cameras]\n\n“The FeverScan M3000P04 is capable of evaluating multiple people in real time” [Published on the FeverScan M3000P04 datasheet, https:\u002F\u002Fwww.cantronics.com\u002Fimages\u002Fdatasheet\u002FFeverScan-M3000P04-.pdf]\n\nYour firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.\n\nYour response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to:\n\nAttn: CAPT Alan Stevens\n\nActing Director, Division of Drug Delivery and General Hospital Devices,\n\nand Human Factors\n\nU.S. Food and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\n\nDocument Control Center (DCC) – WO66-G609\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nRefer to the reference number CMS 613542 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at Jake.Lindstrom@fda.hhs.gov or (301) 796-5716.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC: Dallas Thomas\n\nFDAbasics LLC\n\n15815 SW 11th Court Rd\n\nOcala, FL 34473\n\ndallas@fdabasics.com","Cantronic Systems Inc.","cantronic-systems-inc-613542-03042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcantronic-systems-inc-613542-03042021","2026-10-26T08:08:10.929569+00:00","Closed Out","2021-03-04","613542","2023-07-25","2026-08-20T03:18:47.735+00:00",{"id":71,"raw":72,"subject":77,"body_html":78,"body_text":79,"firm_name":80,"letter_id":81,"created_at":82,"fei_number":20,"letter_url":83,"updated_at":84,"action_type":23,"case_status":24,"posted_date":85,"marcs_cms_no":86,"product_type":87,"closeout_date":20,"issuing_office":76,"recipient_name":88,"body_fetched_at":89,"delivery_method":90,"recipient_title":20,"reference_number":20,"action_taken_date":91,"medical_device_id":20,"response_letter_date":20},2333,[73,74,75,76,77,13,13,13],"\u003Ctime datetime=\"2022-11-21T18:00:00Z\">11\u002F21\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-16T05:00:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcbd-american-shaman-llc-628753-11162022\">CBD American Shaman, LLC\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Unapproved New Drugs\u002FMisbranded\u002FCannabidiol (CBD) Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Stephen Vincent Sanders II\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CBD American Shaman, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2405 Southwest Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kansas City\u003C\u002Fspan>, \u003Cspan>MO\u003C\u002Fspan> \u003Cspan>64108\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@cbdamericanshaman.com\"> support@cbdamericanshaman.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Drug Evaluation and Research\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan> Center for Veterinary Medicine\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>RE: 628753\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sanders:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address CBDAmericanShaman.com in October 2022 and has determined that you take orders there for various human and animal products which you promote as products containing cannabidiol (CBD). We also reviewed your social media websites at www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, which link to your website cbdamericanshaman.com, to purchase your products. FDA has determined that your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)], because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products into interstate commerce under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)].\u003C\u002Fp>\n\n\u003Cp>FDA is particularly concerned that some of your products are in forms that are appealing to children. For example, your CBD Suckers, CBD Hard Candies, various Cookies [with] 10mg CBD per Serving, and various CBD Gummies products are all in forms that would be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children. Furthermore, your products have not been evaluated by the Agency for safety, effectiveness, and quality. As discussed below, CBD has been studied as a drug, and it is the active ingredient in the approved drug product Epidiolex. The use of untested drugs can have unpredictable and unintended consequences, especially in vulnerable populations, such as children. For example, children may be at greater risk for adverse reactions associated with certain drug products due to differences in the ability of children to absorb, metabolize, distribute, or excrete such drug products or their metabolites.\u003C\u002Fp>\n\n\u003Cp>You also market other products that consumers may confuse with traditional foods for humans, including CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey; therefore, with these products there is a risk of unintended consumption of the CBD ingredient by consumers.\u003C\u002Fp>\n\n\u003Cp>In addition, “CBD + ZINC OXIDE Sunscreen” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act [21 U.S.C. 355(a)], and is misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)]. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act [21 U.S.C. 331(d) and (a)]. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>Further, the claims on your website and social media websites establish that your Canine 300 Tincture, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs products, which you promote as products containing CBD for use in pets, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&amp;C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. 351(a)(5)].\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\">https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Human Foods and 301(ll)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are foods to which CBD has been added. We analyzed a sample of your Grandma’s Raisin &amp; Pecan Hermit Cookies and confirmed that the product contains CBD. We also note that you may intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products. Specifically, you describe these gummy products as “adult gummy candy” and\u002For “the perfect way to satisfy your sweet tooth,” and the web pages for three of the products bear Nutrition Facts information.\u003Cbr>\n\u003Cbr>\nAs defined in section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&amp;C Act [21 U.S.C. 348(a)], and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. The available data raise serious concerns about potential harm from CBD added to conventional food. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)] and is subject to the provisions of section 409 of the FD&amp;C Act [21 U.S.C. 348]. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)] because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)]. To the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, they would be adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)] for the same reason.\u003C\u002Fp>\n\n\u003Cp>Further, in regard to your Cookies [with] 10mg CBD per Serving, CBD Suckers, CBD Hard Candies, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey, and, to the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, you should be aware that it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Human Drug and Misbranded Human Drug\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen” is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(C)], because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as sunscreen.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from the product’s labeling, including the claims observed on your website, www.cbdamericanshaman.com, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen . . . BROAD SPECTRUM SPF 35+ UVA • UVB” [from the label on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>“Drug Facts . . . Active Ingredients [s] . . . Cannabidiol (Hemp Exract [sic] (Aerial Parts), Cannabidiol) 0.072% . . . Purpose . . . Sunscreen . . .” [from the label on your website, website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>“This all natural CBD sunscreen lotion is a natural way to protect yourself from harmful UV rays while using an all-natural product that won’t harm you or our planet! This cbd infused sunscreen is 35+ SPF (broad spectrum) and is rated to block UVA and UVB rays. We use Zinc Oxide which is rated safe by EWG on their Skin Deep website and isn't hazardous for the environment like oxybenzone or octinoxate. There is 60mg of nano full-spectrum CBD oil per container.” [from the product information on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\u003C\u002Fp>\n\n\u003Cp>Based on the above labeling claims, “CBD + ZINC OXIDE Sunscreen” is a topical product intended for use as a sunscreen drug. As described below, this sunscreen drug is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>In general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)], if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. 355(a)]. No FDA-approved application pursuant to section 505 of the FD&amp;C Act [21 U.S.C. 355], is in effect for this drug product.\u003C\u002Fp>\n\n\u003Cp>“CBD + ZINC OXIDE Sunscreen” is a sunscreen drug subject to section 505G of the FD&amp;C Act [21 U.S.C. 355h], which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, sunscreen drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> However, this sunscreen drug product does not conform to the conditions of use specified in M020 because the product’s labeling lists CBD as an active ingredient in the Drug Facts panel. CBD is not an active ingredient allowed in any applicable final monograph. Thus, your “CBD + ZINC OXIDE Sunscreen” product does not meet the requirements under section 505G of the FD&amp;C Act, under which it would be deemed to be GRASE and not a new drug.\u003C\u002Fp>\n\n\u003Cp>Furthermore, even if CBD could be considered an inactive ingredient in “CBD + ZINC OXIDE Sunscreen,” this product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&amp;C Act. In particular, such a product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD has no known functional role as an inactive ingredient in a finished drug product.\u003C\u002Fp>\n\n\u003Cp>Additionally, an inactive ingredient should not exert pharmacological effects\u003Csup>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and must be safe when used at the intended dosage.\u003Csup>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> CBD, however, has a known pharmacological activity with demonstrated risks.\u003Csup>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> It is unknown whether the level of CBD used in your “CBD + ZINC OXIDE Sunscreen” drug product has pharmacological activity or poses any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “CBD + ZINC OXIDE Sunscreen” product, that product would not meet the general requirements for legal marketing of nonprescription drugs under sections 505G(a)(1) or (2) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “CBD + ZINC OXIDE Sunscreen” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&amp;C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&amp;C Act. Introduction or delivery for introduction of such product into interstate commerce is prohibited under section 301(d) of the FD&amp;C Act [21 U.S.C. 331(d)].\u003C\u002Fp>\n\n\u003Cp>In addition, “CBD + ZINC OXIDE Sunscreen” is misbranded under section 502(ee) of the FD&amp;C Act [21 U.S.C. 352(ee)] because it is a nonprescription drug subject to section 505G of the FD&amp;C Act [21 U.S.C. 355h], is not the subject of an application approved under section 505 of the FD&amp;C Act [21 U.S.C. 355], and does not comply with the requirements under section 505G of the FD&amp;C Act [21 U.S.C. 355h]. Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act [21 U.S.C. 331(a) and (d)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During our review of your firm’s website cbdamericanshaman.com and your social media websites, www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, FDA determined that your firm is marketing the unapproved new animal drugs Canine 300 Tincture, Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs. Based on our review of your website and social media websites, these products are drugs under section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• On your webpage titled “CBD Dog Treats” under the header “How do CBD dog treats help your pup?”:\u003Cbr>\n&nbsp; o “You can use CBD American Shaman dog treats to relieve your furry friends with high levels of stress. We include CBD oil for dogs in each treat to help calm pets during a storm, firework show, loud party or any other situation that puts them in a state of panic.”\u003Cbr>\n&nbsp; o “They [CBD dog treats] may also help regulate heartbeat and blood pressure”\u003C\u002Fp>\n\n\u003Cp>• On your webpage titled “How To Choose A CBD Oil Product” under the header “Dogs”:\u003Cbr>\n&nbsp; o “If you would like to give your dog CBD every once in a while, like before the vet, for 4th of July fireworks, or when your dog may be extra anxious, we recommend any of our Dog CBD oils (https:\u002F\u002Fcbdamericanshaman.com\u002Fpets) and Soft CBD Dog Treats (https:\u002F\u002Fcbdamericanshaman.com\u002Fsoft-cbd-dog-treats).”\u003Cbr>\n\u003Cbr>\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Cats”:\u003Cbr>\no “Our feline CBD (https:\u002F\u002Fcbdamericanshaman.com\u002Ffeline-cbd-hemp-oil-tincture) oils are also great for when your cat needs help calming down or relaxing before a triggering event.”\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your social media websites that show the intended use of your products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• On your October 13, 2021 Instagram and Facebook posts: “Does your dog need support for #jointhealth or experience storm stress? Our unique recipe of high-quality CBD oil dog treats taste like peanut butter and will leave your pet wanting more.”\u003Cbr>\n• On your February 23, 2018 Facebook post: A photo of a dog is posted by CBD American Shaman with the caption “#funfactfriday: CBD Oil is becoming more and more available for use on pets! In FACT, veterinarians are finding #cbdoil useful in arthritis, stress, digestive issues, and much more.”\u003Cbr>\n&nbsp; o A comment on this post and response from CBD American Shaman:\u003Cbr>\n&nbsp; &nbsp;  Comment from follower: “I am considering trying this for our dog who had seizures.”\u003Cbr>\n&nbsp; &nbsp;  Response from CBD American Shaman: “A lot of people are having success with their dogs [sic] seizures using CBD.”\u003C\u002Fp>\n\n\u003Cp>• On your October 16, 2017 Facebook video post:\u003Cbr>\n&nbsp; o At the 20 second mark in the video a graphic states, “From arthritic canines to anxiety filled equines, CBD Oil is changing the way veterinarians and pet owners treat their furry family members.”\u003Cbr>\n&nbsp; o At the 28 second mark in the video a graphic with the heading “CBD Hemp Oil” states, “Whether a dog has cancer, seizures, or anxiety, cannabis oil can serve as an alternative medication to help treat symptoms.”\u003C\u002Fp>\n\n\u003Cp>• On your September 27, 2017 Facebook post: “Animals have anxiety, joint discomfort, and many of the same disorders as humans. So, just as with our human line of products, we use the best of ingredients for our canine, feline, or equine customers.”\u003C\u002Fp>\n\n\u003Cp>Your CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&amp;C Act [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\u003C\u002Fp>\n\n\u003Cp>To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act [21 U.S.C. 360b, 360ccc, and 360ccc-1]. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&amp;C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&amp;C Act [21 U.S.C. 351(a)(5)]. Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>301(ll) and Adulterated Animal Foods\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Furthermore, it is a prohibited act under section 301(ll) of the FD&amp;C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any animal food, to which has been added a drug approved under section 505 of the FD&amp;C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD, as described above.\u003C\u002Fp>\n\n\u003Cp>According to your product labeling, your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are animal food to which CBD has been added. Specifically, the product labeling depicted on your website, cbdamericanshaman.com, refers to your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, and Horsey Chews, as a “treats.” Additionally, your Doggy Nugs and Kitty Nugs are referred to as food, for example, on your webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Doggy Nugs and states, “If you are seeking CBD benefits for your dog on a daily basis, we recommend our CBD Dog Food, which is made with real chicken and is bowl-licking good.” On the same webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Kitty Nugs and states, “If you are seeking an easy way to give your cat CBD on a daily basis, try our CBD cat food made with real chicken.” Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should also be aware that, as defined in section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the term “food additive” refers to any substance the intended use of which results in its becoming a component of any animal food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.\u003Csup>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in animal food is deemed to be unsafe under section 409(a) of the FD&amp;C Act [21 U.S.C. 348(a)], and causes the animal food to be adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>There is no food additive regulation that authorizes the use of CBD in animal food. Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in animal food. FDA’s regulations in 21 CFR 570.30(a)-(c) describe the criteria for eligibility for classification of an animal food ingredient as GRAS. The use of an animal food substance may be GRAS based on either scientific procedures or, for a substance used in animal food before 1958, through experience based on common use in animal food (see 21 CFR 570.30).\u003C\u002Fp>\n\n\u003Cp>We know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in animal food prior to January 1, 1958. Based on our review of the publicly available literature, the data and information necessary to support the safe use of CBD in animal food are lacking. In fact, literature reports have raised safety concerns for animals consuming CBD, including, but not limited to, male reproductive toxicity and liver toxicity. Therefore, based on our review, the use of CBD in animal products does not satisfy the criteria for GRAS status under 21 CFR 570.30.\u003C\u002Fp>\n\n\u003Cp>FDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in animal food. Therefore, CBD added to animal food is a food additive under section 201(s) of the FD&amp;C Act and is subject to the provisions of section 409 of the FD&amp;C Act [21 U.S.C. 348]. Under section 409 of the FD&amp;C Act [21 U.S.C. 348], an animal food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any animal food. Animal food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your Doggy Chews (all flavors), Soft &amp; Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act. Introduction of this adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>* * *\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>We have the following additional comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>According to the label of your Grandma’s Raisin &amp; Pecan Hermit Cookies [with] 10mg CBD per Serving, the product contains 10 mg CBD per one cookie serving. We collected a sample and analyzed this product and confirmed that the product contains CBD. However, FDA analysis found significantly higher levels of CBD than declared on the label, at 19.3 mg CBD per serving and 17.6 mg CBD per serving in our original and check analyses, respectively. As stated above, failure to accurately list the amount of CBD in the product further increases the risk associated with consumption of the product. We have significant concerns about products marketed with incorrect statements about the amount of CBD, particularly those that contain higher amounts of CBD than labeled because consumers may be consuming more CBD than intended. Nevertheless, even if the product labels were accurate regarding the level of CBD in the product, the product would still be adulterated because it bears or contains an unsafe food additive, as discussed above.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement Labeling\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Information on your website indicates that you intend to market some of your CBD products as dietary supplements. For example, the images of the labels on the product pages of your Rapid Dissolve CBD Tablets, CBD Capsules, VG Cloud Tinctures, Water Soluble Hemp Oil Extract, Gourmet Gummies Hemp Oil Isolate, Gourmet Gummies Energy, CBD Gummies, and Sugar Free Gourmet Gummies all bear the term “dietary supplement.” Your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&amp;C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&amp;C Act [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.\u003Csup>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&amp;C Act, but you may present FDA with any evidence that has bearing on this issue.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 628753” in the subject line of your email.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance &amp; Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the FD&amp;C Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&amp;C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See \u003Cstrong>GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome\u003C\u002Fstrong>). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Section 505G(a)(1) of the FD&amp;C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330, prior to enactment of the CARES Act. In the case of OTC sunscreen drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use. (See Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F\u003C\u002Fa>.)\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 330.1(e).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See&nbsp;\u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s)(5) of the FD&amp;C Act [21 U.S.C. 321(s)(5)], new animal drugs are excluded from the food additive definition. If a new animal drug is unsafe within the meaning of section 512 because it is not approved for use in animal food, then the animal food is adulterated under section 402(a)(2)(C)(ii) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> As noted above, CBD is the active ingredient in the approved drug product Epidiolex and the existence of substantial clinical investigations regarding CBD has been made public.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nProduct:\n\nAnimal & Veterinary\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nStephen Vincent Sanders II\n\nRecipient Title\n\nCEO\n\nCBD American Shaman, LLC\n\n2405 Southwest Blvd.\n\nKansas City, MO 64108\n\nUnited States\n\nsupport@cbdamericanshaman.com\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nCenter for Drug Evaluation and Research\n\nCenter for Veterinary Medicine\n\nWARNING LETTER\n\nNovember 16, 2022\n\nRE: 628753\n\nDear Mr. Sanders:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address CBDAmericanShaman.com in October 2022 and has determined that you take orders there for various human and animal products which you promote as products containing cannabidiol (CBD). We also reviewed your social media websites at www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, which link to your website cbdamericanshaman.com, to purchase your products. FDA has determined that your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)], because they bear or contain an unsafe food additive. Furthermore, it is a prohibited act to introduce your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, CBD Honey, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products into interstate commerce under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)].\n\nFDA is particularly concerned that some of your products are in forms that are appealing to children. For example, your CBD Suckers, CBD Hard Candies, various Cookies [with] 10mg CBD per Serving, and various CBD Gummies products are all in forms that would be attractive to children and could easily be mistaken for traditional foods that are commonly consumed by children. Furthermore, your products have not been evaluated by the Agency for safety, effectiveness, and quality. As discussed below, CBD has been studied as a drug, and it is the active ingredient in the approved drug product Epidiolex. The use of untested drugs can have unpredictable and unintended consequences, especially in vulnerable populations, such as children. For example, children may be at greater risk for adverse reactions associated with certain drug products due to differences in the ability of children to absorb, metabolize, distribute, or excrete such drug products or their metabolites.\n\nYou also market other products that consumers may confuse with traditional foods for humans, including CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey; therefore, with these products there is a risk of unintended consumption of the CBD ingredient by consumers.\n\nIn addition, “CBD + ZINC OXIDE Sunscreen” is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act [21 U.S.C. 355(a)], and is misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)]. Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act [21 U.S.C. 331(d) and (a)]. These violations are described in more detail below.\n\nFurther, the claims on your website and social media websites establish that your Canine 300 Tincture, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs products, which you promote as products containing CBD for use in pets, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. 351(a)(5)].\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov. You can find specific information about how FDA regulates CBD at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-health-focus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nAdulterated Human Foods and 301(ll)\n\nAccording to your product labeling, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are foods to which CBD has been added. We analyzed a sample of your Grandma’s Raisin & Pecan Hermit Cookies and confirmed that the product contains CBD. We also note that you may intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products. Specifically, you describe these gummy products as “adult gummy candy” and\u002For “the perfect way to satisfy your sweet tooth,” and the web pages for three of the products bear Nutrition Facts information.\n\nAs defined in section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the term \"food additive\" refers to any substance the intended use of which results in its becoming a component of any food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.1\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe under section 409(a) of the FD&C Act [21 U.S.C. 348(a)], and causes the food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nThere is no food additive regulation which authorizes the use of CBD. We are not aware of any information to indicate that CBD is the subject of a prior sanction (see 21 CFR Part 181). Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in conventional foods. FDA's regulations in 21 CFR 170.30(a)-(c) describe the criteria for eligibility for classification of a food ingredient as GRAS. The use of a food substance may be GRAS based on either scientific procedures or, for a substance used in food before 1958, through experience based on common use in food (see 21 CFR 170.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in food prior to January 1, 1958. Based on our review of published, scientific literature, existing data and information do not provide an adequate basis to conclude that the use of CBD in food meets the criteria for GRAS status. The available data raise serious concerns about potential harm from CBD added to conventional food. Our review of publicly available data associated with the one FDA-approved CBD drug, as well as our review of published scientific literature, identified potential for liver injury from CBD and potentially harmful interactions with certain drugs. In addition, studies in animals have shown that CBD can interfere with the development and function of testes and sperm, decrease testosterone levels, and impair sexual behavior in males. Therefore, based on our review, the use of CBD in your products does not satisfy the criteria for GRAS status under 21 CFR 170.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in a conventional food. Therefore, CBD added to a conventional food is a food additive under section 201(s) of the FD&C Act [21 U.S.C. 321(s)] and is subject to the provisions of section 409 of the FD&C Act [21 U.S.C. 348]. Under section 409, a food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any conventional food. Food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your CBD Suckers, CBD Hard Candies, Cookies [with] 10mg CBD per Serving, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey products are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)] because they bear or contain an unsafe food additive. Introduction of these adulterated foods into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)]. To the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, they would be adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)] for the same reason.\n\nFurther, in regard to your Cookies [with] 10mg CBD per Serving, CBD Suckers, CBD Hard Candies, CBD Sparkling Tea, CBD Sparkling Water, CBD Coffee, CBD Honey Sticks, and CBD Honey, and, to the extent you intend to promote your 10mg CBD Gummies, CBD Gourmet Gummies, CBD Energy Gummies, and Sugar Free CBD Gourmet Gummies as conventional food products, you should be aware that it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any food, including animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD.2 There is an exception if the substance was marketed in food before the drug was approved or before the substantial clinical investigations involving the drug had been instituted. However, based on the available evidence discussed above, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], prohibits the introduction into interstate commerce of any food to which CBD has been added, but you may present FDA with any evidence bearing on this issue.\n\nUnapproved New Human Drug and Misbranded Human Drug\n\n“CBD + ZINC OXIDE Sunscreen” is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)], because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act [21 U.S.C. 321(g)(1)(C)], because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as sunscreen.\n\nExamples of claims from the product’s labeling, including the claims observed on your website, www.cbdamericanshaman.com, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product includes, but may not be limited to, the following:\n\n“CBD + ZINC OXIDE Sunscreen . . . BROAD SPECTRUM SPF 35+ UVA • UVB” [from the label on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\n“Drug Facts . . . Active Ingredients [s] . . . Cannabidiol (Hemp Exract [sic] (Aerial Parts), Cannabidiol) 0.072% . . . Purpose . . . Sunscreen . . .” [from the label on your website, website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\n“This all natural CBD sunscreen lotion is a natural way to protect yourself from harmful UV rays while using an all-natural product that won’t harm you or our planet! This cbd infused sunscreen is 35+ SPF (broad spectrum) and is rated to block UVA and UVB rays. We use Zinc Oxide which is rated safe by EWG on their Skin Deep website and isn't hazardous for the environment like oxybenzone or octinoxate. There is 60mg of nano full-spectrum CBD oil per container.” [from the product information on your website, https:\u002F\u002Fcbdamericanshaman.com\u002Fcbd-sunscreen]\n\nBased on the above labeling claims, “CBD + ZINC OXIDE Sunscreen” is a topical product intended for use as a sunscreen drug. As described below, this sunscreen drug is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nIn general, a drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. 321(p)], if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling; and in general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act [21 U.S.C. 355(a)]. No FDA-approved application pursuant to section 505 of the FD&C Act [21 U.S.C. 355], is in effect for this drug product.\n\n“CBD + ZINC OXIDE Sunscreen” is a sunscreen drug subject to section 505G of the FD&C Act [21 U.S.C. 355h], which governs nonprescription drugs marketed without an approved application. Under section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. In particular, sunscreen drug products are deemed to be GRASE and not a “new drug” if, among other things, they conform to the conditions of use set forth in the Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use (hereinafter M020).3 However, this sunscreen drug product does not conform to the conditions of use specified in M020 because the product’s labeling lists CBD as an active ingredient in the Drug Facts panel. CBD is not an active ingredient allowed in any applicable final monograph. Thus, your “CBD + ZINC OXIDE Sunscreen” product does not meet the requirements under section 505G of the FD&C Act, under which it would be deemed to be GRASE and not a new drug.\n\nFurthermore, even if CBD could be considered an inactive ingredient in “CBD + ZINC OXIDE Sunscreen,” this product would still need an approved new drug application to be legally marketed because the product would not be eligible for marketing under section 505G of the FD&C Act. In particular, such a product would not meet the conditions under section 505G(a)(1) or (2), insofar as it would not conform with the general requirement in 21 CFR 330.1(e) that inactive ingredients must be safe and suitable.4 A suitable inactive ingredient generally provides a beneficial formulation function, such as a tablet binder or preservative, or improves product delivery (e.g., enhances absorption or controls release of the drug substance).5 CBD has no known functional role as an inactive ingredient in a finished drug product.\n\nAdditionally, an inactive ingredient should not exert pharmacological effects6 and must be safe when used at the intended dosage.7 CBD, however, has a known pharmacological activity with demonstrated risks.8 It is unknown whether the level of CBD used in your “CBD + ZINC OXIDE Sunscreen” drug product has pharmacological activity or poses any concern for safety events. Accordingly, CBD cannot be considered a safe and suitable inactive ingredient as required under 21 CFR 330.1(e). Consequently, if CBD is intended to be an inactive ingredient in your “CBD + ZINC OXIDE Sunscreen” product, that product would not meet the general requirements for legal marketing of nonprescription drugs under sections 505G(a)(1) or (2) of the FD&C Act.\n\nIn addition, FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that “CBD + ZINC OXIDE Sunscreen” is GRASE for use under the conditions prescribed, recommended or suggested in its labeling. Moreover, there is no evident basis under the FD&C Act under which this product would be legally marketed without an approved application. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) of the FD&C Act. Introduction or delivery for introduction of such product into interstate commerce is prohibited under section 301(d) of the FD&C Act [21 U.S.C. 331(d)].\n\nIn addition, “CBD + ZINC OXIDE Sunscreen” is misbranded under section 502(ee) of the FD&C Act [21 U.S.C. 352(ee)] because it is a nonprescription drug subject to section 505G of the FD&C Act [21 U.S.C. 355h], is not the subject of an application approved under section 505 of the FD&C Act [21 U.S.C. 355], and does not comply with the requirements under section 505G of the FD&C Act [21 U.S.C. 355h]. Introduction or delivery for introduction of such a product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act [21 U.S.C. 331(a) and (d)].\n\nUnapproved New Animal Drugs\n\nDuring our review of your firm’s website cbdamericanshaman.com and your social media websites, www.instagram.com\u002Fcbdamerican and www.facebook.com\u002Fcbdamericanshamanproducts, FDA determined that your firm is marketing the unapproved new animal drugs Canine 300 Tincture, Doggy Chews (all flavors), Soft & Tender Doggy Chews, Canine 300 CBD and Terpene Rich Hemp Oil Water Soluble, Feline 300 Tincture, Horsey Chews, Doggy Nugs, and Kitty Nugs. Based on our review of your website and social media websites, these products are drugs under section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)], because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of animals. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.\n\nExamples of claims observed on your website that show the intended use of your products as drugs include, but are not limited to, the following:\n\n• On your webpage titled “CBD Dog Treats” under the header “How do CBD dog treats help your pup?”:\n\no “You can use CBD American Shaman dog treats to relieve your furry friends with high levels of stress. We include CBD oil for dogs in each treat to help calm pets during a storm, firework show, loud party or any other situation that puts them in a state of panic.”\n\no “They [CBD dog treats] may also help regulate heartbeat and blood pressure”\n\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Dogs”:\n\no “If you would like to give your dog CBD every once in a while, like before the vet, for 4th of July fireworks, or when your dog may be extra anxious, we recommend any of our Dog CBD oils (https:\u002F\u002Fcbdamericanshaman.com\u002Fpets) and Soft CBD Dog Treats (https:\u002F\u002Fcbdamericanshaman.com\u002Fsoft-cbd-dog-treats).”\n\n• On your webpage titled “How To Choose A CBD Oil Product” under the header “Cats”:\n\no “Our feline CBD (https:\u002F\u002Fcbdamericanshaman.com\u002Ffeline-cbd-hemp-oil-tincture) oils are also great for when your cat needs help calming down or relaxing before a triggering event.”\n\nExamples of claims observed on your social media websites that show the intended use of your products as drugs include, but are not limited to, the following:\n\n• On your October 13, 2021 Instagram and Facebook posts: “Does your dog need support for #jointhealth or experience storm stress? Our unique recipe of high-quality CBD oil dog treats taste like peanut butter and will leave your pet wanting more.”\n\n• On your February 23, 2018 Facebook post: A photo of a dog is posted by CBD American Shaman with the caption “#funfactfriday: CBD Oil is becoming more and more available for use on pets! In FACT, veterinarians are finding #cbdoil useful in arthritis, stress, digestive issues, and much more.”\n\no A comment on this post and response from CBD American Shaman:\n\n Comment from follower: “I am considering trying this for our dog who had seizures.”\n\n Response from CBD American Shaman: “A lot of people are having success with their dogs [sic] seizures using CBD.”\n\n• On your October 16, 2017 Facebook video post:\n\no At the 20 second mark in the video a graphic states, “From arthritic canines to anxiety filled equines, CBD Oil is changing the way veterinarians and pet owners treat their furry family members.”\n\no At the 28 second mark in the video a graphic with the heading “CBD Hemp Oil” states, “Whether a dog has cancer, seizures, or anxiety, cannabis oil can serve as an alternative medication to help treat symptoms.”\n\n• On your September 27, 2017 Facebook post: “Animals have anxiety, joint discomfort, and many of the same disorders as humans. So, just as with our human line of products, we use the best of ingredients for our canine, feline, or equine customers.”\n\nYour CBD-containing products for animals are “new animal drugs” under section 201(v) of the FD&C Act [21 U.S.C. 321(v)], because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling.\n\nTo be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act [21 U.S.C. 360b, 360ccc, and 360ccc-1]. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act [21 U.S.C. 360b(a)], and adulterated under section 501(a)(5) of the FD&C Act [21 U.S.C. 351(a)(5)]. Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\n301(ll) and Adulterated Animal Foods\n\nFurthermore, it is a prohibited act under section 301(ll) of the FD&C Act [21 U.S.C. 331(ll)], to introduce or deliver for introduction into interstate commerce any animal food, to which has been added a drug approved under section 505 of the FD&C Act or for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public. Based on available evidence, FDA has concluded that the prohibition in section 301(ll) applies to CBD, as described above.\n\nAccording to your product labeling, your Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs products are animal food to which CBD has been added. Specifically, the product labeling depicted on your website, cbdamericanshaman.com, refers to your Doggy Chews (all flavors), Soft & Tender Doggy Chews, and Horsey Chews, as a “treats.” Additionally, your Doggy Nugs and Kitty Nugs are referred to as food, for example, on your webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Doggy Nugs and states, “If you are seeking CBD benefits for your dog on a daily basis, we recommend our CBD Dog Food, which is made with real chicken and is bowl-licking good.” On the same webpage titled, “How To Choose A CBD Oil Product,” a link is provided to the product page for your Kitty Nugs and states, “If you are seeking an easy way to give your cat CBD on a daily basis, try our CBD cat food made with real chicken.” Therefore, the introduction or delivery for introduction into interstate commerce of this product is a prohibited act under section 301(ll) of the FD&C Act.\n\nYou should also be aware that, as defined in section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the term “food additive” refers to any substance the intended use of which results in its becoming a component of any animal food, unless the substance is generally recognized as safe (GRAS) among qualified experts under the conditions of its intended use, or unless the substance meets a listed exception.9\n\nFood additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in animal food is deemed to be unsafe under section 409(a) of the FD&C Act [21 U.S.C. 348(a)], and causes the animal food to be adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Introduction of an adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nThere is no food additive regulation that authorizes the use of CBD in animal food. Furthermore, we are not aware of any basis to conclude that CBD is GRAS for use in animal food. FDA’s regulations in 21 CFR 570.30(a)-(c) describe the criteria for eligibility for classification of an animal food ingredient as GRAS. The use of an animal food substance may be GRAS based on either scientific procedures or, for a substance used in animal food before 1958, through experience based on common use in animal food (see 21 CFR 570.30).\n\nWe know of no basis for general recognition of safety for CBD based either on scientific procedures or common use in animal food prior to January 1, 1958. Based on our review of the publicly available literature, the data and information necessary to support the safe use of CBD in animal food are lacking. In fact, literature reports have raised safety concerns for animals consuming CBD, including, but not limited to, male reproductive toxicity and liver toxicity. Therefore, based on our review, the use of CBD in animal products does not satisfy the criteria for GRAS status under 21 CFR 570.30.\n\nFDA is not aware of any other exception to the food additive definition that would apply to CBD for use as an ingredient in animal food. Therefore, CBD added to animal food is a food additive under section 201(s) of the FD&C Act and is subject to the provisions of section 409 of the FD&C Act [21 U.S.C. 348]. Under section 409 of the FD&C Act [21 U.S.C. 348], an animal food additive is deemed unsafe unless it is approved by FDA for its intended use prior to marketing. CBD is not approved for use in any animal food. Animal food containing an unsafe food additive within the meaning of section 409 is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. Therefore, your Doggy Chews (all flavors), Soft & Tender Doggy Chews, Horsey Chews, Doggy Nugs, and Kitty Nugs are adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act. Introduction of this adulterated animal food into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\n* * *\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nWe have the following additional comments:\n\nAccording to the label of your Grandma’s Raisin & Pecan Hermit Cookies [with] 10mg CBD per Serving, the product contains 10 mg CBD per one cookie serving. We collected a sample and analyzed this product and confirmed that the product contains CBD. However, FDA analysis found significantly higher levels of CBD than declared on the label, at 19.3 mg CBD per serving and 17.6 mg CBD per serving in our original and check analyses, respectively. As stated above, failure to accurately list the amount of CBD in the product further increases the risk associated with consumption of the product. We have significant concerns about products marketed with incorrect statements about the amount of CBD, particularly those that contain higher amounts of CBD than labeled because consumers may be consuming more CBD than intended. Nevertheless, even if the product labels were accurate regarding the level of CBD in the product, the product would still be adulterated because it bears or contains an unsafe food additive, as discussed above.\n\nDietary Supplement Labeling\n\nInformation on your website indicates that you intend to market some of your CBD products as dietary supplements. For example, the images of the labels on the product pages of your Rapid Dissolve CBD Tablets, CBD Capsules, VG Cloud Tinctures, Water Soluble Hemp Oil Extract, Gourmet Gummies Hemp Oil Isolate, Gourmet Gummies Energy, CBD Gummies, and Sugar Free Gourmet Gummies all bear the term “dietary supplement.” Your products cannot be dietary supplements because they do not meet the definition of a dietary supplement under section 201(ff) of the FD&C Act [21 U.S.C. 321(ff)]. FDA has concluded, based on available evidence, that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act [21 U.S.C. 321(ff)(3)(B)(i) and (ii)]. Under those provisions, if an article (such as CBD) is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act [21 U.S.C. 355], or has been authorized for investigation as a new drug for which substantial clinical investigations have been instituted and for which the existence of such investigations has been made public, then products containing that substance are outside the definition of a dietary supplement.10 There is an exception if the substance was “marketed as” a dietary supplement or as a conventional food before the new drug investigations were authorized; however, based on available evidence, FDA has concluded that this is not the case for CBD. FDA is not aware of any evidence that would call into question its current conclusion that CBD products are excluded from the dietary supplement definition under sections 201(ff)(3)(B)(i) and (ii) of the FD&C Act, but you may present FDA with any evidence that has bearing on this issue.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct these violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to CFSANResponse@fda.hhs.gov. Please include “CMS 628753” in the subject line of your email.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nCarolyn E. Becker\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance & Compliance\n\nCenter for Veterinary Medicine\n\nFood and Drug Administration\n\n_____________________\n\n1 Under section 201(s) of the FD&C Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food, (2) pesticide chemicals, (3) color additives, (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the FD&C Act, the Poultry Products Inspection Act, or the Meat Inspection Act), (5) new animal drugs, and (6) dietary ingredients in or intended for use in a dietary supplement.\n\n2 CBD is the active ingredient in the approved drug product Epidiolex. Furthermore, the existence of substantial clinical investigations regarding CBD has been made public. For example, two such substantial clinical investigations include GW Pharmaceuticals’ investigations regarding Sativex and Epidiolex. (See GW Pharmaceuticals Receives Investigational New Drug (IND) from FDA for Phase 2\u002F3 Clinical Trial of Epidiolex in the Treatment of Dravet Syndrome). FDA considers a substance to be “authorized for investigation as a new drug” if it is the subject of an Investigational New Drug application (IND) that has gone into effect. Under 21 CFR 312.2, unless a clinical investigation meets the limited criteria in that regulation, an IND is required for all clinical investigations of products that are subject to section 505 of the FD&C Act.\n\n3 Section 505G(a)(1) of the FD&C Act specifies criteria under which certain nonprescription drugs without an approved application are deemed GRASE and not \"new drugs\", notably conformance with conditions detailed in applicable OTC monograph documents issued by FDA under 21 CFR 330, prior to enactment of the CARES Act. In the case of OTC sunscreen drug products, relevant documents were deemed under section 505G to be a final administrative order, Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use. (See Order ID OTC000006, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.)\n\n4 21 CFR 330.1(e) requires that “the product contains only suitable inactive ingredients which are safe in the amounts administered and do not interfere with the effectiveness of the preparation or with suitable tests or assays to determine if the product meets its professed standards of identity, strength, quality, and purity.”\n\n5 See e.g., \"Using the Inactive Ingredient Database\" Guidance for Industry (July 2019), p. 1 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F128687\u002Fdownload, and \"Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients\" Guidance for Industry (May 2005), pp. 1-2 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F72260\u002Fdownload.\n\n6 See e.g., 21 CFR 314.3(b) and 21 CFR 210.3(b)(7), which define an active ingredient as “any component that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man.” All other components of a finished drug product are considered inactive ingredients (see CFR 314.3(b), 21 CFR 210.3(b)(8)).\n\n7 See 21 CFR 330.1(e).\n\n8 For example, the labeling for Epidiolex (cannabidiol) prescription oral solution includes risks for the drug such as liver injury, interactions with other drugs or supplements, potential for male reproductive toxicity, somnolence, insomnia, diarrhea, decreased appetite, abdominal pain, upset stomach, changes in mood, irritability, and agitation. See https:\u002F\u002Fwww.accessdata.fda.gov\u002Fdrugsatfda_docs\u002Flabel\u002F2020\u002F210365s005s006s007lbl.pdf.\n\n9 Under section 201(s)(5) of the FD&C Act [21 U.S.C. 321(s)(5)], new animal drugs are excluded from the food additive definition. If a new animal drug is unsafe within the meaning of section 512 because it is not approved for use in animal food, then the animal food is adulterated under section 402(a)(2)(C)(ii) of the FD&C Act.\n\n10 As noted above, CBD is the active ingredient in the approved drug product Epidiolex and the existence of substantial clinical investigations regarding CBD has been made public.","CBD American Shaman, LLC","cbd-american-shaman-llc-628753-11162022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcbd-american-shaman-llc-628753-11162022","2026-10-26T08:08:12.074684+00:00","2022-11-21","628753","Animal & VeterinaryDrugsFood & Beverages","Stephen Vincent Sanders II","2026-08-20T01:25:12.266+00:00","Via Overnight Delivery","2022-11-16",4,{"510k":94,"classification":95,"enforcement":96,"event":97,"event_backfill":98,"pma":99,"warning_letter":100},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]